{{Rsnum
|rsid=10038196
|Gene=ADCY2
|Chromosome=5
|position=7517305
|Orientation=plus
|GMAF=0.4252
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
|Gene_s=ADCY2
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 27.4 | 45.1 | 27.4
| HCB | 3.6 | 32.8 | 63.5
| JPT | 3.6 | 23.2 | 73.2
| YRI | 23.1 | 56.5 | 20.4
| ASW | 38.6 | 52.6 | 8.8
| CHB | 3.6 | 32.8 | 63.5
| CHD | 2.8 | 33.9 | 63.3
| GIH | 26.7 | 51.5 | 21.8
| LWK | 33.6 | 52.7 | 13.6
| MEX | 13.8 | 44.8 | 41.4
| MKK | 24.4 | 53.8 | 21.8
| TSI | 24.5 | 56.9 | 18.6
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs10038196
|Name_s=
|Gene_s=ADCY2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.00002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109306
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs10038196
|overall_frequency_n=73
|overall_frequency_d=128
|overall_frequency=0.570312
|n_genomes=42
|n_genomes_annotated=0
|n_haplomes=61
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}